Maria Carmen Mir

Maria Carmen Mir

Auto-generated profile, based on publicly available information

Maria Carmen Mir

Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in European Urology Oncology
Verified
Journal Article
Closed access
MMMaria Carmen Mir
Maria Carmen Mir
UCUmberto Capitanio
Umberto Capitanio
Riccardo BertoloRiccardo Bertolo
Riccardo Bertolo
IOIdir Ouzaid
Idir Ouzaid
MSMaciej Salagierski
Maciej Salagierski
PPPhillip M. Pierorazio
Phillip M. Pierorazio

Verified
Journal Article
Open access
PDF file
FCFrancesco Claps
Francesco Claps
NPNicola Pavan
Nicola Pavan
LOLuca Ongaro
Luca Ongaro
DTDomenico Tierno
Domenico Tierno
Gabriele GrassiGabriele Grassi
Gabriele Grassi
Bruna Scaggiante,Bruna Scaggiante,
Bruna Scaggiante,
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract urothelial carcinoma (UTUC) and bladder carcinoma (BC) as the most common cancers among UCs (90–95%). BC is the most common cancer and can be a highly heterogeneous disease, including both non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) forms with different oncologic outcomes. Approximately 80% of new BC diagnoses are classified as NMIBC after the initial transurethral resection of the bladder tumor (TURBt). In this setting, intravesical instillation of Bacillus Calmette–Guerin (BCG) is the current standard treatment for intermediate- and high-risk patients. Unfortunately, recurrence occurs in 30% to 40% of patients despite adequate BCG treatment. Radical cystectomy (RC) is currently considered the standard treatment for NMIBC that does not respond to BCG. However, RC is a complex surgical procedure with a recognized high perioperative morbidity that is dependent on the patient, disease behaviors, and surgical factors and is associated with a significant impact on quality of life. Therefore, there is an unmet clinical need for alternative bladder-preserving treatments for patients who desire a bladder-sparing approach or are too frail for major surgery. In this review, we aim to present the strategies in BCG-unresponsive NMIBC, focusing on novel molecular therapeutic targets.

16 June 2023 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
RCRiccardo Campi
Riccardo Campi
GRGiacomo Rebez
Giacomo Rebez
Tobias KlatteTobias Klatte
Tobias Klatte
EREduard Roussel
Eduard Roussel
IOIdir Ouizad
Idir Ouizad
MMMaria Carmen Mir
Maria Carmen Mir

20 February 2023 in BJU International
Verified
Journal Article
Closed access
FCFrancesco Claps
Francesco Claps
MKMaaike W. van de Kamp
Maaike W. van de Kamp
RMRoman Mayr
Roman Mayr
PBPeter J. Bostrom
Peter J. Bostrom
SSShahrokh F. Shariat
Shahrokh F. Shariat
BRBas W.G. van Rhijn
Bas W.G. van Rhijn

31 March 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
ABAaron W. Bradshaw
Aaron W. Bradshaw
RARiccardo Autorino
Riccardo Autorino
GSGiuseppe Simone
Giuseppe Simone
BYBo Yang
Bo Yang
RURobert G. Uzzo
Robert G. Uzzo
IDIthaar Derweesh
Ithaar Derweesh

23 March 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
KSKamini Singh
Kamini Singh
ASArishya Sharma
Arishya Sharma
MMMaria C Mir
Maria C Mir
JDJudith A Drazba
Judith A Drazba
WHWarren Heston
Warren Heston
AAAlexandru Almasan
Alexandru Almasan
Macroautophagy is a catabolic process that can mediate cell death or survival. Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment (TR) is known to induce autophagy. Here we investigated whether SQSTM1/p62 (p62) overexpression, as a marker of autophagic flux, was related to aggressiveness of human prostate cancer (PCa) and whether autophagy regulated the treatment response in sensitive but not resistant PCa cell lines.